To test the hypothesis, we integrated whole-genome breast cancer sequencing data from 560 primary tumors (referred to as BRCA-EU) [4] with ChIP-seq identified ER binding events obtained from > 20 primary as well as metastatic ER-positive breast tumors (referred to as ER ChIP-seq) [23]. This evidence concerns the gene ESR1 and breast carcinoma.